Nalm6-bearing mice infused with a limiting dose of CD19.BBζ CAR-T cells and pulsed with dasatinib using a 3-day dasatinib/4-day off schedule exhibited more durable anti-tumor responses and improved survival compared to mice treated with vehicle or dasatinib every other day (Fig. 7, A and B, and fig. Here, CD19 is linked to neoplasm.